ACE-031 vs BYM338
Head-to-head comparison of ACE-031 (ACE-031 (soluble activin receptor type IIB-Fc)) and BYM338 (Bimagrumab (BYM338)) — benefits, dosing, side effects, research data, and where to buy.
| Property | ACE-031 | BYM338 |
|---|---|---|
| Category | Muscle & Performance | Muscle & Performance |
| Full Name | ACE-031 (soluble activin receptor type IIB-Fc) | Bimagrumab (BYM338) |
| Molecular Weight | ~95 kDa | ~148 kDa |
| Half-Life | Days to weeks | ~2-3 weeks |
| Amino Acids | N/A | N/A |
| Typical Dose | 0.1-3 mg/kg in early studies | 10-30 mg/kg IV in trials |
| Route | Subcutaneous | Intravenous |
| Purity | ≥98% | ≥98% |
| Studies Count | 75 | 140 |
| Research Status | Clinical | Clinical |
ACE-031 Benefits
- ✓myostatin/activin neutralization
- ✓lean mass gain
- ✓muscle function support
- ✓anti-catabolic effect
BYM338 Benefits
- ✓increased lean mass
- ✓functional strength support
- ✓reduced muscle wasting
- ✓metabolic body-composition shift
ACE-031 Dosing
Clinical studies used single or repeated SC doses|dose escalation in mg/kg|monitoring for edema/bleeding
BYM338 Dosing
IV infusion|10-30 mg/kg per study cycle|repeat every 4-12 weeks
ACE-031 Side Effects
- ⚠telangiectasia/vascular effects
- ⚠epistaxis
- ⚠headache/edema
BYM338 Side Effects
- ⚠muscle cramps
- ⚠diarrhea/nausea
- ⚠infusion reactions
Research Overview
ACE-031
ACE-031 produced increases in lean mass in early studies, but development was curtailed after safety concerns and variable efficacy. Its literature remains important because it validated activin receptor blockade as a muscle-building strategy.
BYM338
Clinical trials showed meaningful increases in lean mass, with mixed functional outcomes depending on population and endpoint. The antibody remains one of the best-documented receptor-blocking approaches to muscle anabolism in humans.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.